[go: up one dir, main page]

PE20110121A1 - Composiciones farmaceuticas de aliskiren - Google Patents

Composiciones farmaceuticas de aliskiren

Info

Publication number
PE20110121A1
PE20110121A1 PE2010000272A PE2010000272A PE20110121A1 PE 20110121 A1 PE20110121 A1 PE 20110121A1 PE 2010000272 A PE2010000272 A PE 2010000272A PE 2010000272 A PE2010000272 A PE 2010000272A PE 20110121 A1 PE20110121 A1 PE 20110121A1
Authority
PE
Peru
Prior art keywords
aliskiren
cross
cellulose
stearate
linked
Prior art date
Application number
PE2010000272A
Other languages
English (en)
Inventor
Petra Gisela Rigassi-Dietrich
Martin Schimd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20110121A1 publication Critical patent/PE20110121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA SOLIDA DE DOSIFICACION ORAL QUE COMPRENDE: A) ALISKIREN O UNA SAL FARMACEUTICAMENTE ACEPTABLE EN UNA CANTIDAD MAYOR A 46% EN PESO BASADO EN PESO TOTAL; B) RELLENO SELECCIONADO DE UNO O MAS DE CELULOSA MICROCRISTALINA, ALMIDON DE PAPA, ALMIDON DE TRIGO, HIDROXIPROPILCELULOSA, AZUCAR DE CONFITERIA, DEXTRINA; C) UN AGLUTINANTE SELECCIONADO DE UNO O MAS DE POLIVINILPIRROLIDONAS, POLIETILENGLICOLES Y HPMC; D) DESINTEGRANTE SELECCIONADO DE UNO O MAS POLIVINILPIRROLIDONA ENTRECRUZADA, CARBOXIMETILCELULOSA ENTRECRUZADA, ACIDO ALGINICO, GOMA GUAR Y CARBOXIMETILCELULOSA; E) DESLIZANTE SELECCIONADO DE UNO O MAS SILICA COLOIDAL, DIOXIDO DE SILICIO COLOIDAL, CELULOSA EN POLVO, ENTRE OTROS; F) LUBRICANTE SELECCIONADO DE UNO O MAS DE ESTEARATO DE MAGNESIO, ESTEARTO DE ALUMINIO, ESTEARATO DE CALCIO, ACEITE DE CASTOR HIDROGENADO, ENTRE OTROS. DICHA FORMA FARMACEUTICA. DICHA FORMULACION PERMITE LA FORMULACION ROBUSTA DE ALISKIREN UTIL EN EL TRATAMIENTO DE HIPERTENSION O FALLA CARDIACA CONGESTIVA
PE2010000272A 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren PE20110121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55387804P 2004-03-17 2004-03-17

Publications (1)

Publication Number Publication Date
PE20110121A1 true PE20110121A1 (es) 2011-02-28

Family

ID=34994415

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren
PE2005000288A PE20060075A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren
PE2010000272A PE20110121A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren
PE2005000288A PE20060075A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren

Country Status (24)

Country Link
US (3) US8617595B2 (es)
EP (2) EP2283826B1 (es)
JP (2) JP2007529456A (es)
KR (2) KR101353736B1 (es)
CN (2) CN103462913A (es)
AR (1) AR048431A1 (es)
AU (2) AU2005224010B2 (es)
BR (1) BRPI0508833A (es)
CA (1) CA2554633C (es)
EC (1) ECSP066807A (es)
ES (1) ES2747941T3 (es)
IL (1) IL177424A0 (es)
MA (1) MA28490B1 (es)
MX (1) MX347617B (es)
MY (2) MY148773A (es)
NO (1) NO343217B1 (es)
NZ (1) NZ548823A (es)
PE (3) PE20142101A1 (es)
RU (3) RU2384328C2 (es)
SG (1) SG153830A1 (es)
TN (1) TNSN06294A1 (es)
TW (1) TWI406656B (es)
WO (1) WO2005089729A2 (es)
ZA (1) ZA200606220B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560821B8 (en) * 2002-11-05 2010-05-19 Glaxo Group Limited Antibacterial agents
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
CA2645260A1 (en) * 2006-04-03 2007-10-18 Novartis Ag Renin inhibitors for the treatment of hypertension
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
PE20081157A1 (es) * 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno
PE20081167A1 (es) * 2006-11-09 2008-10-03 Novartis Ag Sal de alisquireno
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
AR068539A1 (es) 2007-09-28 2009-11-18 Novartis Ag Formulaciones galenicas de compuestos organicos
KR20100063090A (ko) * 2007-09-28 2010-06-10 노파르티스 아게 알리스키렌 및 발사르탄의 생약 제제
ATE505203T1 (de) * 2007-09-28 2011-04-15 Novartis Ag Pharmazeutische kombination aus aliskiren und valsartan
BRPI0822652A2 (pt) 2007-11-13 2015-06-23 Teva Pharmáceutica Ind Ltd Petach Tirva 49131 Fórmulas polimórficas de hemifumarato de alisquireno e processos para a sua preparação
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009149344A2 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
US20100093603A1 (en) * 2008-07-17 2010-04-15 Kenneth Baker Use of organic compounds
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
US9026212B2 (en) 2008-09-23 2015-05-05 Incube Labs, Llc Energy harvesting mechanism for medical devices
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
CN102300558A (zh) 2009-01-28 2011-12-28 诺瓦提斯公司 有机化合物的盖伦制剂
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2393489B1 (en) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
AR075880A1 (es) 2009-03-20 2011-05-04 Novartis Ag Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo.
BRPI1009131A2 (pt) * 2009-03-20 2016-03-01 Novartis Ag composição farmacêutica compreendendo aliscireno
JP2010280601A (ja) * 2009-06-04 2010-12-16 Suntory Holdings Ltd キシロオリゴ糖高含有錠剤
US20120220663A1 (en) 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
CN103536576B (zh) * 2013-10-15 2015-07-01 海南卫康制药(潜山)有限公司 阿利吉仑组合物胶囊
RU2545833C1 (ru) * 2013-12-03 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US20030187038A1 (en) 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
JP2003015880A (ja) * 2001-06-29 2003-01-17 Toshiba Corp 携帯情報端末およびアドインプログラム起動方法
CN1571668A (zh) * 2001-10-18 2005-01-26 诺瓦提斯公司 At1－受体拮抗剂和心血管药物形成的盐
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
CA2485081C (en) * 2002-05-17 2013-01-08 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
AU2003255527A1 (en) * 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings

Also Published As

Publication number Publication date
AU2005224010A1 (en) 2005-09-29
MY144477A (en) 2011-09-30
ZA200606220B (en) 2008-04-30
WO2005089729A2 (en) 2005-09-29
CN103462913A (zh) 2013-12-25
ECSP066807A (es) 2006-11-16
RU2006136090A (ru) 2008-04-27
WO2005089729A3 (en) 2006-10-12
EP2283826A3 (en) 2013-08-07
CA2554633A1 (en) 2006-09-29
NO20064670L (no) 2006-10-16
MY148773A (en) 2013-05-31
AU2005224010B2 (en) 2009-02-26
AU2009202069B2 (en) 2012-02-16
NZ548823A (en) 2011-02-25
PE20060075A1 (es) 2006-03-20
RU2480210C1 (ru) 2013-04-27
MA28490B1 (fr) 2007-03-01
AR048431A1 (es) 2006-04-26
SG153830A1 (en) 2009-07-29
US8007824B2 (en) 2011-08-30
KR20070006776A (ko) 2007-01-11
RU2384328C2 (ru) 2010-03-20
CN1997354B (zh) 2013-09-11
CA2554633C (en) 2014-07-08
CN1997354A (zh) 2007-07-11
EP1729736A2 (en) 2006-12-13
KR101353736B1 (ko) 2014-01-22
RU2011135405A (ru) 2013-03-10
US20050272790A1 (en) 2005-12-08
US20060018960A1 (en) 2006-01-26
KR20130028803A (ko) 2013-03-19
RU2438661C2 (ru) 2012-01-10
US8617595B2 (en) 2013-12-31
TNSN06294A1 (en) 2007-12-03
ES2747941T3 (es) 2020-03-12
TW200534843A (en) 2005-11-01
AU2009202069A1 (en) 2009-06-18
JP2007529456A (ja) 2007-10-25
IL177424A0 (en) 2008-03-20
US7683054B2 (en) 2010-03-23
EP2283826B1 (en) 2019-09-04
TWI406656B (zh) 2013-09-01
EP2283826A2 (en) 2011-02-16
MX347617B (es) 2017-05-04
JP5925607B2 (ja) 2016-05-25
JP2012211152A (ja) 2012-11-01
KR101274855B1 (ko) 2013-06-13
PE20142101A1 (es) 2014-12-27
US20070197655A1 (en) 2007-08-23
RU2009138446A (ru) 2011-04-27
BRPI0508833A (pt) 2007-08-14
NO343217B1 (no) 2018-12-03

Similar Documents

Publication Publication Date Title
PE20110121A1 (es) Composiciones farmaceuticas de aliskiren
AR109571A2 (es) Composición de trazodona para administración una vez por día
MX2010003923A (es) Formulacion farmaceutica de valsartan.
JP2010047612A5 (es)
IL179718A0 (en) Pharmaceutical composition containing irbesartan
SG152240A1 (en) Pharmaceutical compositions comprising an amphiphilic starch
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
MX343358B (es) Tabletas de acetato de ulipristal.
EP2493312A4 (en) SOLID PHARMACEUTICAL COMPOSITIONS WITH AN INTEGRASE INHIBITOR
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
MX2010007462A (es) Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.
TW200621317A (en) Pharmaceutical composition
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
JP2018527305A5 (es)
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
PE20120990A1 (es) Formulaciones de alisquireno e hidroclorotiazida
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
WO2008012474A3 (fr) Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
WO2007006738A3 (en) Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
FC Refusal